Cargando…
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
BACKGROUND: Inflammatory mediators, including acute phase reactants and cytokines, have been reported to be associated with clinical efficacy in patients with melanoma and other cancers receiving immune checkpoint inhibitors (ICI). Analyses of patient sera from three large phase II/III randomized IC...
Autores principales: | Laino, Andressa S, Woods, David, Vassallo, Melinda, Qian, Xiaozhong, Tang, Hao, Wind-Rotolo, Megan, Weber, Jeffrey |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312339/ https://www.ncbi.nlm.nih.gov/pubmed/32581042 http://dx.doi.org/10.1136/jitc-2020-000842 |
Ejemplares similares
-
C reactive protein impairs adaptive immunity in immune cells of patients with melanoma
por: Yoshida, Tatsuya, et al.
Publicado: (2020) -
Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade
por: Johannet, Paul, et al.
Publicado: (2022) -
Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
por: Khushalani, Nikhil I, et al.
Publicado: (2022) -
Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020) -
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
por: Curti, Brendan, et al.
Publicado: (2020)